CLINICAL TRIAL / NCT02181218

Inclusion Criteria: - Able to understand and voluntarily sign an informed consent form - Age ≥ 18 at time of informed consent - Diagnosis of one of the following: - relapsed/refractory peripheral T-cell lymphoma of any subtype including mycosis fungoides and Sézary syndrome of advanced stage (IIB-IVB) **for the expansion cohort:patients must have biopsy-proven T-cell lymphoma and measurable disease. - relapsed/refractory DLBCL (up to 6 DLBCL patients are allowed in the dose-escalation portion of the study) - relapsed/refractory HL Note: extracorporeal photopheresis is NOT considered a systemic therapy for this study. - Transplant eligible (as determined by referring physician) patients who have failed one prior salvage therapy or transplant ineligible (as determined by referring physician) patients who have failed one prior therapy - ECOG performance status of ≤ 2 - Laboratory test results within the following ranges: - Absolute neutrophil count ≥ 1500/mm³ - Platelet count ≥ 100,000/mm³ - Total bilirubin ≤ 1.5 x ULN - AST (SGOT) and ALT (SGPT) ≤ 3 x ULN - Creatinine < 2 mg/dL - Potassium ≥ 3.3 mmol/L or at/above the lower limit of normal for the performing laboratory - Magnesium ≥ 1.4 mg/dL or at/above the lower limit of normal for the performing laboratory. - Negative serum pregnancy test for women of childbearing potential - Washout time of at least 4 weeks for prior biological, chemotherapeutic, or radiotherapy Exclusion Criteria: - Any serious medical condition, laboratory abnormality, or psychiatric illness that would - in the opinion of the investigator - prevent the subject from signing the informed consent form - Pregnant or lactating women - Any medical condition or laboratory abnormalities, which - in the opinion of the investigator - places the subject at unacceptable risk, or confounds the ability to interpret data if he/she were to participate in the study - Positive CSF cytology during staging, symptomatic leptomeningeal involvement, or parenchymal involvement of brain or spinal cord - Prior allogeneic hematopoietic cell transplant - Prior solid organ transplant - Cirrhotic liver disease from any cause - Known HIV infection - Impaired cardiac function or clinically significant cardiac disease including any of the following: - Congenital long QT syndrome - Screening ECG with QTc interval ≥ 500 milliseconds - Myocardial infarction (MI) or unstable angina ≤ 6 months of C1D1; however, subjects with a history of MI between 6 and 12 months who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event would be eligible - Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV. In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present - An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present - Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (defined here as ventricular rate < 50 bpm); right bundle-branch block + left anterior hemi-block (bifasicular block) - Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix 9) and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI History or presence of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest - Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes - Uncontrolled hypertension, i.e., blood pressure (BP) of ≥160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria - Any cardiac arrhythmia requiring an anti-arrhythmic medication, excluding stable (i.e., at least 30 days from screening) doses of beta-blockers - Concomitant use of drugs that may cause significant QT prolongation and/or torsades de pointes that cannot be discontinued or switched to a different medication prior to treatment - Concomitant use of CYP3A4 inhibitors or inducers unless able to stop medication(s) prior to starting study treatment - Patients who are unwilling to stop the use of herbal remedies while receiving study treatment - Unable to accept blood product transfusions - Men whose sexual partners are women of childbearing potential not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom - Concurrent malignancy requiring active therapy *Patients with localized prostate cancer having undergone surgery or radiation (field confined to ≤ 30% of marrow-bearing bone) at least 30 days prior to study treatment are eligible